CNBC Television published this video item, entitled “GlaxoSmithKline CEO on spinoff of consumer health-care business” – below is their description.
GlaxoSmithKline’s stock rose 3.5% in the premarket Wednesday after it detailed plans to spin out its consumer health-care business into a separate company. Glaxo will eventually receive an $11 billion payment from the new company. GlaxoSmithKline CEO Emma Walmsley joined “Squawk Box” on Wednesday to discuss.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.
About This Source - CNBC Television
CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.
As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.
Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co.
GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization‘s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.
In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.